Baastrup’s Syndrome Market

Market Overview:

The 7 major baastrup’s syndrome markets reached a value of USD 1,435.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2,189.9 Million by ​2035​, exhibiting a growth rate (CAGR) of 3.91% during ​2025-2035​.

The baastrup’s syndrome market has been comprehensively analyzed in IMARC's new report titled "Baastrup’s Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". Baastrup's syndrome, or "kissing spine syndrome," is a degenerative spinal disorder where adjacent spinous processes have abnormal contact, causing inflammation, focal pain, and limited motion. It most often occurs in the lumbar spine and is commonly found in conjunction with age-related spinal degeneration, hyperlordosis of the lumbar spine, or repetitive strain of the spine. Patients with this syndrome characteristically present with chronic back pain that is increased by extension of the spine, tenderness at involved vertebrae, and, in some, radiating pain. Diagnosis of Baastrup's syndrome is made by a combination of clinical evaluation and imaging methods like X-rays, MRI, or CT scans, which show narrowing of interspinous spaces, soft tissue thickening, and degenerative changes. The condition is typically found in elderly populations as a result of continuous spinal degeneration; however, younger individuals involved in physically active jobs can also experience the disorder, and this raises the prevalence and market importance.

The rising incidence of age-related spinal degeneration and mechanical loading on the spine is a major driver for the growth of the Baastrup's syndrome market. As the population is aging, degenerative spinal conditions like Baastrup's syndrome are increasingly being seen, and this is resulting in an increased demand for successful treatment methods. Moreover, lifestyle patterns like extended sitting, bad posture, and excessive physical exertion among sports persons and hard workers are escalating the risk of acquiring this disorder. Increased concern for spinal well-being and improvement in diagnostic imaging technology, such as MRI and CT scans, has led to better early detection and precise diagnosis, facilitating increased market growth. Furthermore, the increasing use of minimally invasive treatments, for example, corticosteroid injections and radiofrequency ablation, is augmenting treatment success and patient satisfaction. The advent of regenerative treatments, for instance, platelet-rich plasma (PRP) injections and stem cell therapy, offers new avenues for managing disease. Finally, the increased emphasis on non-invasive care, such as physiotherapy, chiropractic, and customized rehabilitation programs, is likely to play a major role in driving market growth through the forecast period.

IMARC Group's new report provides an exhaustive analysis of the baastrup’s syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the baastrup’s syndrome market in any manner.

Recent Developments:

• In July 2022, research explored Baastrup’s syndrome in young gymnasts, a less common demographic for the condition. Two female athletes suffering from chronic back pain were treated with different minimally invasive interventions—one with an interspinous ligament injection and the other with a medial branch block. Both experienced significant symptom relief and were able to return to gymnastics, demonstrating that such treatments may be effective for managing Baastrup’s syndrome in physically active individuals.

Key Highlights:

• Research on 375 individuals undergoing lumbar spine MRI found that 37.8% showed indications of Baastrup’s disease.
• The condition becomes more common with age, with the highest prevalence observed in individuals aged 80 and older, where it affects 87.5% of cases.
• The L4–L5 segment is impacted in 35.5% of cases, making it the most frequently affected level, followed by L5–S1 at 29.4% and L3–L4 at 24.7%.
• Among diagnosed patients, 71.6% have the disease at multiple spinal levels, with 59.4% of these cases involving two levels and 40.6% affecting three or more levels.
• Baastrup’s disease frequently occurs alongside other degenerative spine conditions, including disc bulging (65.3%), disc herniation (41.9%), Modic changes (54.9%), facet osteoarthritis (41.6%), and spinal stenosis (25.1%).

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the baastrup’s syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the baastrup’s syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current baastrup’s syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the baastrup’s syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the baastrup’s syndrome market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the baastrup’s syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​​2019-2035​​) of baastrup’s syndrome across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of baastrup’s syndrome by age across the seven major markets?
• What is the number of prevalent cases (​​2019-2035​​) of baastrup’s syndrome by gender across the seven major markets?
• How many patients are diagnosed (​​2019-2035​​) with baastrup’s syndrome across the seven major markets?
• What is the size of the baastrup’s syndrome patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of baastrup’s syndrome?
• What will be the growth rate of patients across the seven major markets?

Baastrup’s Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for baastrup’s syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the baastrup’s syndrome market?
• What are the key regulatory events related to the baastrup’s syndrome market?
• What is the structure of clinical trial landscape by status related to the baastrup’s syndrome market?
• What is the structure of clinical trial landscape by phase related to the baastrup’s syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the baastrup’s syndrome market?